RSK signaling drives cancer growth and drug resistance.
Targeting RSK, at the junction of two critical signaling pathways (more durable efficacy) and downstream in the MAPK pathway (safer and less toxic) makes us unique.
Activated RSK is highly expressed and has been identified as a novel target in multiple cancers.
RSK was undruggable until now.
PMD-026 is the first orally available RSK kinase inhibitor.
We have overcome the chemistry challenge through precision mapping.
By leveraging computational modelling and state-of-the-art medicinal chemistry. PMD-026 is a highly selective inhibitor and an entirely new way to treat cancer. PMD-026 is designed to be taken orally, which is more convenient and less disruptive to patient’s lives.
First-in-class & best-in-class.
Differentiated safety and efficacy.
PMD-026 shrank TNBC tumors in 100% of the mice evaluated.
A PMD-026 and Paclitaxel (PTX) combination is synergistic leading to accelerated tumor regression.
